Historical Valuation
Vistagen Therapeutics Inc (VTGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 59.46 is considered Undervalued compared with the five-year average of -3.56. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.12 to 4.10 according to relative valuation methord. Compared to the current price of 0.66 USD , Vistagen Therapeutics Inc is Undervalued By 41.05%.
Relative Value
Fair Zone
1.12-4.10
Current Price：0.66
41.05%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Vistagen Therapeutics Inc (VTGN) has a current Price-to-Book (P/B) ratio of 0.40. Compared to its 3-year average P/B ratio of 1.63 , the current P/B ratio is approximately -75.52% higher. Relative to its 5-year average P/B ratio of 2.47, the current P/B ratio is about -83.90% higher. Vistagen Therapeutics Inc (VTGN) has a Forward Free Cash Flow (FCF) yield of approximately -198.23%. Compared to its 3-year average FCF yield of -75.37%, the current FCF yield is approximately 162.99% lower. Relative to its 5-year average FCF yield of -66.66% , the current FCF yield is about 197.39% lower.
P/B
Median3y
1.63
Median5y
2.47
FCF Yield
Median3y
-75.37
Median5y
-66.66
Competitors Valuation Multiple
AI Analysis for VTGN
The average P/S ratio for VTGN competitors is 16.35, providing a benchmark for relative valuation. Vistagen Therapeutics Inc Corp (VTGN.O) exhibits a P/S ratio of 59.46, which is 263.67% above the industry average. Given its robust revenue growth of 40.98%, this premium appears sustainable.
Performance Decomposition
AI Analysis for VTGN
1Y
3Y
5Y
Market capitalization of VTGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VTGN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VTGN currently overvalued or undervalued?
Vistagen Therapeutics Inc (VTGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 59.46 is considered Undervalued compared with the five-year average of -3.56. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.12 to 4.10 according to relative valuation methord. Compared to the current price of 0.66 USD , Vistagen Therapeutics Inc is Undervalued By 41.05% .
What is Vistagen Therapeutics Inc (VTGN) fair value?
VTGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.12 to 4.10 according to relative valuation methord.
How does VTGN's valuation metrics compare to the industry average?
The average P/S ratio for VTGN's competitors is 16.35, providing a benchmark for relative valuation. Vistagen Therapeutics Inc Corp (VTGN) exhibits a P/S ratio of 59.46, which is 263.67% above the industry average. Given its robust revenue growth of 40.98%, this premium appears sustainable.
What is the current P/B ratio for Vistagen Therapeutics Inc (VTGN) as of Jan 09 2026?
As of Jan 09 2026, Vistagen Therapeutics Inc (VTGN) has a P/B ratio of 0.40. This indicates that the market values VTGN at 0.40 times its book value.
What is the current FCF Yield for Vistagen Therapeutics Inc (VTGN) as of Jan 09 2026?
As of Jan 09 2026, Vistagen Therapeutics Inc (VTGN) has a FCF Yield of -198.23%. This means that for every dollar of Vistagen Therapeutics Inc’s market capitalization, the company generates -198.23 cents in free cash flow.
What is the current Forward P/E ratio for Vistagen Therapeutics Inc (VTGN) as of Jan 09 2026?
As of Jan 09 2026, Vistagen Therapeutics Inc (VTGN) has a Forward P/E ratio of -0.46. This means the market is willing to pay $-0.46 for every dollar of Vistagen Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Vistagen Therapeutics Inc (VTGN) as of Jan 09 2026?
As of Jan 09 2026, Vistagen Therapeutics Inc (VTGN) has a Forward P/S ratio of 59.46. This means the market is valuing VTGN at $59.46 for every dollar of expected revenue over the next 12 months.